Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
House dust mite organism" is not a specific molecular target but refers to the entire organism. The relevant therapeutic targets are the **major allergens** produced by house dust mites, particularly proteins such as **Der p 2** and **Der f 2**, which are responsible for triggering allergic reactions in humans. These allergens have a beta-barrel structure similar to immunoglobulin folds and induce strong Th2-type immune responses that can lead to asthma, rhinitis, and eczema in susceptible individuals[1][3]. The high sequence and structural similarity between group 2 allergens from different species suggests similar biological functions across mites[4]. These proteins are not receptors or enzymes but act as environmental antigens/allergens. Note: "House dust mite organism" is too broad for a molecular target entry; the correct entries should be individual allergens such as "House dust mite allergen Der p 2".
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on House dust mite allergen Der p 2 (or Der f 2, depending on species) (Der p 2 (for Dermatophagoides pteronyssinus), Der f 2 (for Dermatophagoides farinae)).